米托蒽醌灌注预防膀胱癌术后复发的疗效观察(附98例报告)

目的　评价米托蒽醌 (MTZ)膀胱灌注预防浅表性膀胱癌术后复发的疗效和安全性。方法　对 98例浅表性膀胱癌患者行TURBT或膀胱部分切除术 ,术后 1周予MTZ 12mg 生理盐水 5 0ml膀胱内灌注 ,药物于膀胱内保留 2h ,每周 1次 ,连续 8周 ,以后每月 1次 ,连续 12个月。定期做血尿常规、肝肾功能及膀胱镜检查 ,并记录每次膀胱灌注后的全身及局部反应。　结果　 98例均未见全身性药物不良反应 ,随访 6～ 2 4个月 ,平均 13个月 ,复发 6例 ,复发率 6 .2 %。　结论　MTZ膀胱灌注防止膀胱癌术后复发疗效满意 ,安全性好

Intravesical instillation of mitoxantrone for the prevention of postoperative recurrence of bladder cancer

Objective To evaluate intravesical instillation of mitoxantrone(MTZ) for the prevention of postoperative recurrence of bladder cancer. Methods Intravesical instillation of 12 mg MTZ dissolved in 50 ml normal saline and retained in bladder for 2 hours were given to bladder cancer patients postoperatively once a week for 8 weeks and subsequently once a month for 12 months.Kidney and liver function,blood counting,urinalysis and cystoscopy were taken periodically.The systemic and local reactions were recorded every time after the intravesical instillation. Results All of the 98 cases were followed up for 6 to 24 months with a mean of 13 months.The recurrence rate was 6.2%.There was no generalized side effect. Conclusions Intravesical instillation of MTZ was efficacious for the prevention of postoperative recurrence of superficial bladder cancer with safety and less side effect.So it can be widely used in such patients.